Filing Analysis
Tenax Therapeutics, Inc. announced topline results from its Phase 3 LEVEL clinical trial for TNX-103 in patients with PH-HFpEF on August 10, 2026.
📋 Key Facts
- Announcement of topline results from the Phase 3 LEVEL clinical trial.
- The trial evaluated TNX-103 in patients with Pulmonary Hypertension with preserved Ejection Fraction (PH-HFpEF).
- Company hosted a conference call and live webcast on August 10, 2026, to discuss results.
Tenax Therapeutics, Inc. filed an 8-K to announce the release of its financial results for the second quarter ended June 30, 2026.
📋 Key Facts
- Reporting period: Second Quarter ended June 30, 2026.
- Filing date: July 31, 2026.
- The filing includes a press release (Exhibit 99.1) detailing the company's financial condition and results of operations.
Tenax Therapeutics, Inc. announced it will present Phase 3 LEVEL clinical trial results at the European Society of Cardiology (ESC) Congress 2026. The company expects to release topline data from this trial in August 2026.
📋 Key Facts
- Company will present Phase 3 LEVEL clinical trial results at the ESC Congress 2026 in a Late-Breaking Clinical Science session.
- Topline data for the Phase 3 LEVEL clinical trial is expected in August 2026.
Tenax Therapeutics entered into a Supply Agreement with Orion Corporation for the manufacture of its orally administered levosimendan product. Additionally, the parties executed a Sixth Amendment to their existing License Agreement, extending regulatory milestone deadlines through 2035.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Entered into a Supply Agreement with Orion Corporation on June 29, 2026.
- Orion will be the primary supplier of the Oral Product for development and potential commercial use.
- The Supply Agreement includes cost-sharing provisions for scaling up manufacturing capabilities.
- Initial term is five years from first delivery, with automatic three-year renewals.
- Sixth Amendment to License Agreement extends the US regulatory approval milestone deadline to December 31, 2035.
- Amendment requires compliance with Orion's information and cybersecurity requirements.
Tenax Therapeutics, Inc. has amended the employment agreements of its top three executives and adopted new company-wide Change in Control (CIC) and Severance Plans. These changes align executive compensation with broader employee benefit structures regarding terminations and acquisitions.
🚩 Red Flags
- Increased cash severance liabilities in the event of an acquisition or leadership turnover.
📋 Key Facts
- On June 26, 2026, the Board approved amendments to employment agreements for Christopher Giordano (CEO), Thomas Staab, and Stuart Rich.
- The amendments provide severance benefits based on a newly adopted CIC Plan and Severance Plan.
- In non-CIC terminations without cause, executives receive 12 months of base salary plus one month per year of service (max 12 extra months) and pro-rated bonuses.
- In Change in Control scenarios, CEO Christopher Giordano is entitled to 18 months of base salary and accelerated vesting; other executives are entitled to 12 months.
- The company adopted a 'double trigger' CIC Plan for eligible employees, requiring both a change in control and termination without cause/for good reason for benefits to vest.
Tenax Therapeutics reported the results of its 2026 annual meeting of stockholders held on June 2, 2026. The stockholders elected the Board of Directors for one-year terms and ratified the appointment of Cherry Bekaert LLP as the independent auditor for the fiscal year ending December 31, 2026.
📋 Key Facts
- Annual Meeting held on June 2, 2026.
- Seven directors were elected to one-year terms expiring in 2027: June Almenoff, Michael Davidson, Declan Doogan, Christopher T. Giordano, Robyn M. Hunter, Gerald T. Proehl, and Stuart Rich.
- Cherry Bekaert LLP was ratified as the independent registered public accounting firm for 2026 with 21,304,543 votes in favor.
Tenax Therapeutics, Inc. reported its financial results for the first quarter ended March 31, 2026. The disclosure was made via a press release attached as an exhibit to the 8-K filing.
📋 Key Facts
- The filing was made on May 12, 2026, reporting results for the quarter ended March 31, 2026.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- The press release is included as Exhibit 99.1.
- The filing was signed by Christopher T. Giordano, President and Chief Executive Officer.
Tenax Therapeutics has appointed Thomas R. Staab, II as Chief Financial Officer, effective May 11, 2026, replacing interim CFO Thomas A. McGauley. Mr. Staab brings extensive executive experience from BioCryst Pharmaceuticals and LENSAR, and his compensation package includes significant equity inducements.
📋 Key Facts
- Thomas R. Staab, II appointed as CFO effective May 11, 2026.
- Interim CFO Thomas A. McGauley will resign effective May 10, 2026, but will remain as principal financial officer through the filing of the Q1 2026 Form 10-Q.
- Mr. Staab's compensation includes an annual base salary of $428,000 and a 45% target bonus.
- Inducement equity awards consist of 10,000 restricted stock units (RSUs) and options to purchase 450,000 shares of common stock.
- Mr. Staab previously served as CFO of LENSAR, Inc. (NASDAQ: LNSR) and BioCryst Pharmaceuticals (NASDAQ: BCRX).
Tenax Therapeutics, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2025. The disclosure was made via a press release on March 10, 2026, and filed under Item 2.02.
📋 Key Facts
- Financial results cover the fourth quarter and full year ended December 31, 2025.
- The report was filed on March 10, 2026.
- The filing includes Exhibit 99.1, which is the press release containing the detailed financial results.
Tenax Therapeutics, Inc. announced a second amendment to the employment agreement of its Chief Medical Officer, Dr. Stuart Rich. Effective January 1, 2026, Dr. Rich will transition to a part-time schedule, working an average of four days per week with a prorated base salary.
🚩 Red Flags
- Reduction in executive time commitment (CMO moving to part-time status).
📋 Key Facts
- Effective date of employment amendment: January 1, 2026.
- Dr. Stuart Rich (CMO) will now work an average of four days per week.
- Annual base salary for Dr. Rich will be prorated to reflect the modified work schedule.
- The Board approved the modification on December 22, 2025.
Tenax Therapeutics announced positive results from a Blinded Sample Size Re-estimation (BSSR) for its Phase 3 LEVEL trial of TNX-103. The re-estimation confirms the trial is powered at over 90% to meet its primary endpoint, maintaining existing enrollment and data timelines.
📋 Key Facts
- Blinded Sample Size Re-estimation (BSSR) for the Phase 3 LEVEL trial of TNX-103 was successful.
- The trial is now powered at >90% to detect a 25 meter change in 6-minute walk distance (6MWD).
- Target enrollment numbers and expected topline data timeframes remain unchanged.
- Company has initiated the global Phase 3 LEVEL-2 study for TNX-103 in PH-HFpEF patients.
Tenax Therapeutics, Inc. announced its financial results for the third quarter ended September 30, 2025. The filing serves as a formal notification of the release of quarterly earnings data.
📋 Key Facts
- Reporting period: Third Quarter ended September 30, 2025.
- Filing date: November 12, 2025.
- The company issued a press release (Exhibit 99.1) containing the financial results.
Tenax Therapeutics, Inc. announced that the European Patent Office (EPO) has issued an Intention to Grant a patent for TNX-103 (oral levosimendan) and related formulations for treating pulmonary hypertension in PH-HFpEF patients.
📋 Key Facts
- The EPO notified the Company of its 'Intention to Grant' a patent.
- Patent coverage includes TNX-103 (oral levosimendan), other levosimendan formulations, and active metabolites.
- Target indication is pulmonary hypertension resulting from heart failure with preserved ejection fraction (PH-HFpEF).
- Filing date: September 16, 2025.
Tenax Therapeutics, Inc. has amended its long-standing license agreement with Orion Corporation to expand its rights regarding levosimendan. The amendment grants Tenax exclusive worldwide rights for orally-administered pharmaceutical products containing levosimendan and adds manufacturing rights for subcutaneous versions.
📋 Key Facts
- Amendment dated September 3, 2025, to the original License Agreement from September 20, 2013.
- Expanded rights include exclusive worldwide development, commercialization, and manufacturing of orally-administered levosimendan products.
- Added manufacturing/subcontracting rights for existing subcutaneous levosimendan products.
- Orion Corporation will supply levosimendan for oral product development at a price in the 'low triple-digit thousands in Euros per kilogram'.
- The agreement has undergone multiple previous amendments (2020, 2022, 2024).
Tenax Therapeutics, Inc. filed an 8-K to announce its financial results for the second quarter ended June 30, 2025. The filing serves as a formal announcement of the earnings release issued on August 13, 2025.
📋 Key Facts
- Reporting period: Second Quarter ended June 30, 2025.
- Filing date: August 13, 2025.
- The filing includes a press release (Exhibit 99.1) detailing the financial results.
Tenax Therapeutics, Inc. reported the results of its 2025 annual meeting of stockholders held on June 11, 2025. Key outcomes included the approval of an officer exculpation amendment and the election of seven directors.
🚩 Red Flags
- Stockholders rejected Proposal 3 regarding the method of stockholder action, indicating some dissatisfaction with corporate governance structures/flexibility.
📋 Key Facts
- Stockholders approved the 'Officer Exculpation Amendment' to the Certificate of Incorporation on June 11, 2025.
- Seven directors were elected for one-year terms expiring in 2026: June Almenoff, Michael Davidson, Declan Doogan, Christopher T. Giordano, Robyn M. Hunter, Gerald T. Proehl, and Stuart Rich.
- The Officer Exculpation Amendment was filed with the DE Secretary of State on June 13, 2025, and became effective immediately.
- A restated certificate of incorporation integrating the amendment was filed on June 16, 2025.
- Stockholders rejected a proposal to require all stockholder action to be taken at meetings (Proposal 3).
- The appointment of Cherry Bekaert LLP as independent auditor for FY2025 was ratified.
- Say-on-pay frequency was set to every two years following a nonbinding advisory vote.
Tenax Therapeutics, Inc. issued an 8-K to announce its financial results for the first quarter ended March 31, 2025.
📋 Key Facts
- The filing was made on May 14, 2025.
- Reporting period: First Quarter ended March 31, 2025.
- The company issued a press release (Exhibit 99.1) containing the financial results.
Tenax Therapeutics, Inc. issued an 8-K to announce its financial results for the fourth quarter and full year ended December 31, 2024.
📋 Key Facts
- Report date: March 25, 2025
- Reporting period: Q4 and Full Year ended December 31, 2024
- The filing includes a press release as Exhibit 99.1 regarding financial results.
Tenax Therapeutics, Inc. completed a $25 million private placement of common stock and pre-funded warrants to entities managed by RTW Investments, LP. The proceeds are intended to fund Phase 3 clinical trials and provide a cash runway through the end of 2027.
🚩 Red Flags
- Significant dilution potential due to the issuance of pre-funded warrants covering up to 10x the number of common shares issued in the placement.
- Pre-funded warrants have a nominal exercise price ($0.01), effectively acting as immediate equity upon registration.
- Beneficial ownership limitations for purchasers (9.99% or 19.99%) suggest structured institutional investment often seen in micro-cap financing.
📋 Key Facts
- Private placement closed on March 5, 2025.
- Gross proceeds: approximately $25 million (before fees).
- Securities issued: 378,346 shares of common stock at $6.04 per share and pre-funded warrants to purchase up to 3,760,726 shares at $6.03 per warrant.
- Pre-funded warrants have an exercise price of $0.01 and do not expire.
- The company entered into a registration rights agreement requiring the filing of a resale registration statement within 45 days.
- Liquidated damages clause: 1.0% monthly penalty if registration statement is not declared effective by specified deadlines.
- Post-transaction outstanding shares: 3,965,385 common stock shares.
Tenax Therapeutics, Inc. has appointed Thomas A. McGauley as Interim Chief Financial Officer, effective December 2, 2024. He replaces Lawrence R. Hoffman in this capacity and will serve via a consulting agreement with Danforth Advisors, LLC.
🚩 Red Flags
- Use of interim/contracted personnel for key financial roles (CFO) can sometimes indicate instability or rapid turnover in finance leadership.
- The transition from one interim officer to another suggests a lack of permanent financial leadership at this stage.
📋 Key Facts
- Thomas A. McGauley appointed as Interim CFO, Principal Financial Officer, and Principal Accounting Officer on Dec 2, 2024.
- McGauley is being provided through Danforth Advisors, LLC under an existing consulting agreement.
- Compensation for services is set at $410 per hour, with a potential annual increase of up to 4%.
- Lawrence R. Hoffman has transitioned out of the Interim CFO role.
Tenax Therapeutics, Inc. issued an 8-K to announce its financial results for the third quarter ended September 30, 2024.
📋 Key Facts
- The filing is a standard announcement of quarterly earnings (Q3 2024).
- Report date: November 13, 2024.
- Period covered: Third quarter ended September 30, 2024.
Tenax Therapeutics, Inc. held a special meeting of stockholders on October 25, 2024, where shareholders approved an amendment to the company's 2022 Stock Incentive Plan. The amendment significantly increases the number of shares authorized for issuance under the plan.
🚩 Red Flags
- Significant increase in share authorization (approx. 7.9M shares) which can lead to future dilution of existing shareholders.
📋 Key Facts
- Stockholders approved Amendment No. 2 to the 2022 Stock Incentive Plan on October 25, 2024.
- The amendment increases total shares authorized for issuance under the plan to 8,336,600 shares.
- This represents an increase of 7,935,912 shares from previous levels.
- Stockholders also approved a proposal to adjourn the Special Meeting if necessary to allow for further proxy solicitation.
Tenax Therapeutics, Inc. filed an 8-K to announce its financial results for the second quarter ended June 30, 2024. The filing serves as a formal announcement of the earnings release issued on August 13, 2024.
📋 Key Facts
- Reporting period: Second Quarter ended June 30, 2024
- Filing date: August 13, 2024
- The filing includes a press release (Exhibit 99.1) detailing financial results and operations.
Tenax Therapeutics, Inc. announced the successful closing of a private placement that generated approximately $100 million in gross proceeds.
📋 Key Facts
- Closing date: August 12, 2024
- Total gross proceeds from private placement: approximately $100 million
- The announcement was made via a press release attached as Exhibit 99.1
Tenax Therapeutics announced a $100 million private placement of common stock, pre-funded warrants, and warrants to fund Phase 3 clinical trials through the end of 2027. The offering includes significant warrant coverage that will result in substantial dilution upon exercise or topline data announcements.
🚩 Red Flags
- Significant potential dilution: The number of shares underlying warrants (approx. 48.5M) significantly exceeds the current outstanding common stock (3.4M).
- Warrant expiration tied to clinical data: Warrants expire shortly after topline data announcement, likely triggering massive conversion/dilution at a critical value inflection point.
- Pre-funded warrants with $0.01 exercise price effectively act as immediate equity dilution.
📋 Key Facts
- Private placement expected to close on August 8, 2024.
- Gross proceeds estimated at approximately $100 million before fees.
- Issuance of 1,450,661 shares of common stock and pre-funded warrants for up to 31,882,671 shares.
- Accompanying warrants issued for up to 16,666,666 shares with an exercise price of $4.50.
- Pre-funded warrants have an exercise price of $0.01 and do not expire.
- Warrants expire upon the earlier of topline data from Phase 3 LEVEL trial announcement or August 8, 2029.
- Company expects proceeds to extend cash runway through the end of 2027.
- Leerink Partners acting as lead placement agent; Guggenheim Securities and William Blair as joint agents.
Tenax Therapeutics reported the results of its 2024 annual meeting of stockholders, which included the approval of an amendment to the company's stock incentive plan and the election of several directors. Additionally, the company announced a modified employment agreement for its Chief Medical Officer.
🚩 Red Flags
- Reduction in CMO work schedule/compensation may indicate a shift in clinical focus or resource management, though it is framed as a voluntary amendment.
📋 Key Facts
- Stockholders approved Amendment No. 1 to the 2022 Stock Incentive Plan, increasing authorized shares under the plan by 400,000 to a total of 400,688 shares.
- Chief Medical Officer Dr. Stuart Rich entered into an employment agreement amendment effective June 15, 2024, reducing his work schedule to three days per week with a prorated base salary (current annual base: $333,900).
- Seven directors were elected to the Board for one-year terms expiring in 2025.
- Stockholders ratified Cherry Bekaert LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
Tenax Therapeutics, Inc. filed an 8-K to announce its financial results for the first quarter ended March 31, 2024.
📋 Key Facts
- Report date: May 14, 2024
- Reporting period: First quarter ended March 31, 2024
- The filing includes a press release regarding results of operations and financial condition (Exhibit 99.1).
Tenax Therapeutics, Inc. filed an 8-K to announce its financial results for the fiscal year ended December 31, 2023.
📋 Key Facts
- The filing was made on March 28, 2024.
- The report covers financial results for the year ended December 31, 2023.
- A press release containing the detailed results was issued as Exhibit 99.1.
Tenax Therapeutics, Inc. has regained compliance with Nasdaq's Minimum Float Requirement after receiving written confirmation from Nasdaq that the company now meets the 500,000 publicly held shares threshold.
🚩 Red Flags
- Historical delisting risk (previously failed minimum float requirement).
📋 Key Facts
- Nasdaq confirmed on February 22, 2024, that the Company has over 500,000 publicly held shares of common stock.
- The company has regained compliance with Nasdaq Listing Rule 5550(a)(4) (Minimum Float Requirement).
- Nasdaq stated that the matter regarding non-compliance is now closed.
- The company had previously been notified of non-compliance on January 11, 2024.
Tenax Therapeutics, Inc. entered into an amendment to its 2013 License Agreement with Orion Corporation on February 19, 2024. The amendment expands the Company's geographic rights for levosimendan-based products worldwide but introduces significant new milestone payment obligations.
🚩 Red Flags
- Significant contingent liabilities: Up to $45.0 million in non-refundable commercialization milestones based on sales performance.
- Increased milestone obligations: Significant cash outflows ($15M combined for US and Japan approvals) triggered by regulatory success.
📋 Key Facts
- Expanded geographic scope: Exclusive right to develop/commercialize certain levosimendan-based products is now worldwide (previously limited to US and Canada).
- Increased FDA Milestone: Payment due to Orion upon US FDA approval increased to $10.0 million.
- New Japan Milestone: Added a $5.0 million milestone payment due upon regulatory approval in Japan.
- Sales-based Milestones: Increased non-refundable commercialization milestones totaling up to $45.0 million contingent on cumulative worldwide sales.
- Royalty Reduction: Reduced tiered royalties based on worldwide net sales.
- Supply Agreement Benefit: Reduced the maximum price per capsule for oral levosimendan-based product under a pending supply agreement.
Tenax Therapeutics, Inc. completed a registered public offering of common stock, pre-funded warrants, and accompanying warrants on February 12, 2024. The offering raised approximately $9.0 million in gross proceeds to fund company operations.
🚩 Red Flags
- Significant dilution potential due to the issuance of up to 3.2 million common warrants (nearly double the current outstanding shares).
- Pre-funded warrants issued at $0.001 exercise price effectively function as immediate equity for large holders.
📋 Key Facts
- Gross proceeds from the Public Offering: approximately $9.0 million.
- Estimated net proceeds: approximately $8.0 million after fees and expenses.
- Offering components: 421,260 shares of common stock, 1,178,740 pre-funded warrants, and up to 3,200,000 common warrants.
- Pricing: $5.65 per share/warrant (or $5.649 for pre-funded warrants).
- Common Warrants exercise price: $5.65; expiration: 5 years.
- Pre-Funded Warrants exercise price: $0.001; no expiration date.
- Placement Agent fee: 6.5% of gross proceeds plus expenses/legal fees.
- Lock-up period: Company and officers/directors are restricted from selling securities for 90 days following closing.
Tenax Therapeutics announced the enrollment of the first patient in its Phase 3 LEVEL study for TNX-103, targeting pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF). This represents a significant clinical milestone in the company's lead drug development program.
📋 Key Facts
- First patient enrolled in the Phase 3 LEVEL study on February 7, 2024.
- The study evaluates TNX-103 (oral levosimendan).
- Target indication is pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF).
Tenax Therapeutics announced that the USPTO has allowed a patent covering various formulations of levosimendan (TNX-101, 102, and 103) for improving exercise performance in PH-HFpEF patients. This represents a significant intellectual property milestone for their lead drug candidates.
📋 Key Facts
- USPTO allowed a patent covering the use of TNX-103 (oral), TNX-102 (subcutaneous), and TNX-101 (IV) levosimendan.
- Patent claims also cover active metabolites OR1896 and OR18955, as well as combinations with other cardiovascular drugs.
- The patent is specifically targeted at improving exercise performance in patients with PH-HFpEF (Pulmonary Hypertension with Heart Failure with preserved Ejection Fraction).
Tenax Therapeutics, Inc. has regained compliance with the Nasdaq Bid Price Rule after its stock closed at $1.00 or greater for ten consecutive trading days. This resolves a delisting risk that had been under extension since March 2023.
🚩 Red Flags
- Historical history of price non-compliance (stock trading below $1.00 for 30 consecutive business days prior to March 29, 2023).
📋 Key Facts
- The Company achieved a closing price of $1.00 or greater for ten consecutive trading days from January 3, 2024, to January 17, 2024.
- Nasdaq confirmed the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) (the 'Bid Price Rule').
- The matter regarding the previous non-compliance notice is now considered closed by Nasdaq.
- A prior extension had been granted on September 28, 2023, which was valid through March 25, 2024.
Tenax Therapeutics received a notice from Nasdaq regarding non-compliance with the minimum publicly held shares requirement (500,000 shares) following a 1-for-80 reverse stock split. Additionally, the company appointed an Interim CFO to succeed Eliot M. Lurier, who passed away in December 2023.
🚩 Red Flags
- Delisting notice regarding minimum share requirements (Rule 5550(a)(4)).
- Recent 1-for-80 reverse stock split, which often indicates extreme downward pressure on share price.
- Sudden vacancy in the CFO role due to the death of the previous officer.
- Use of an interim contractor for a critical financial role.
📋 Key Facts
- Nasdaq notified the company on January 11, 2024, of non-compliance with Nasdaq Listing Rule 5550(a)(4) regarding minimum publicly held shares.
- The non-compliance was triggered by a 1-for-80 reverse stock split effected around January 3, 2024.
- The company must provide a compliance plan to Nasdaq by February 26, 2024.
- Lawrence R. Hoffman appointed as Interim CFO effective January 11, 2024, via Danforth Advisors, LLC.
- Interim CFO compensation is set at $416 per hour under an existing consulting agreement.
Tenax Therapeutics, Inc. has implemented a 1-for-80 reverse stock split effective January 2, 2024. The action was taken to regain compliance with Nasdaq's $1.00 minimum bid price requirement.
🚩 Red Flags
- Reverse stock split (often a sign of extreme share price depreciation and distress).
- Imminent delisting risk/Non-compliance with Nasdaq's $1.00 minimum bid price rule.
- Significant reduction in the number of shares outstanding.
📋 Key Facts
- Reverse stock split ratio: 1 share for every 80 shares outstanding.
- Effective date of the reverse split: January 2, 2024, at 5:00 p.m.
- Pre-split shares outstanding: 23,862,434.
- Post-split shares outstanding: approximately 298,281.
- Purpose of split: To assist in regaining compliance with Nasdaq Listing Rule 5550(a)(2) regarding the $1.00 minimum bid price requirement.